CU20180136A7 - Anticuerpos monoclonales aislados que compiten por la union a tau con el anticuerpo 16g7 - Google Patents

Anticuerpos monoclonales aislados que compiten por la union a tau con el anticuerpo 16g7

Info

Publication number
CU20180136A7
CU20180136A7 CU2018000136A CU20180136A CU20180136A7 CU 20180136 A7 CU20180136 A7 CU 20180136A7 CU 2018000136 A CU2018000136 A CU 2018000136A CU 20180136 A CU20180136 A CU 20180136A CU 20180136 A7 CU20180136 A7 CU 20180136A7
Authority
CU
Cuba
Prior art keywords
tau
antibody
antibodies
isolated monoclonal
rating
Prior art date
Application number
CU2018000136A
Other languages
English (en)
Other versions
CU24537B1 (es
Inventor
Svetlana Alexander
Robin Barbour
Philip James Dolan
Yue Liu
Mark Renz
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of CU20180136A7 publication Critical patent/CU20180136A7/es
Publication of CU24537B1 publication Critical patent/CU24537B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

<p><!--EndFragment--><!--StartFragment-->La invención proporciona anticuerpos que específicamente se unen a tau. Los anticuerpos inhiben o retrasan las patologías asociadas con tau y deterioro sintomático asociado. En un aspecto ,la invención proporciona un anticuerpo monoclonal aislado que se une específicamente a tau. Los ejemplos de dichos anticuerpos se unen a un epítopo dentro de los residuos de aminoácidos 55-78, 60-75 o 61-70 de la SEQ ID NO: 3 (correspondientes a los residuos de aminoácidos 113-136, 118-133 o 119-128, respectivamente de SEQ ID NO: 1). Algunos de estos anticuerpos compiten por unirse a una tau humana con el anticuerpo 16G7. Algunos de estos anticuerpos se unen al mismo epítopo en la tau humana como 16G7.<!--EndFragment--></p>
CU2018000136A 2016-05-02 2017-05-02 Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 3d6 CU24537B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662330789P 2016-05-02 2016-05-02
PCT/IB2017/052544 WO2017191560A1 (en) 2016-05-02 2017-05-02 Antibodies recognizing tau

Publications (2)

Publication Number Publication Date
CU20180136A7 true CU20180136A7 (es) 2019-06-04
CU24537B1 CU24537B1 (es) 2021-07-02

Family

ID=58709515

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2018000136A CU24537B1 (es) 2016-05-02 2017-05-02 Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 3d6

Country Status (21)

Country Link
US (3) US10889638B2 (es)
EP (1) EP3452508A1 (es)
JP (2) JP7481726B2 (es)
KR (1) KR102471787B1 (es)
CN (1) CN109219615B (es)
AU (1) AU2017259038B2 (es)
CA (1) CA3022515A1 (es)
CL (1) CL2018003112A1 (es)
CO (1) CO2018012986A2 (es)
CU (1) CU24537B1 (es)
EA (1) EA201892417A1 (es)
IL (1) IL262726B2 (es)
MX (1) MX2018013384A (es)
MY (1) MY198194A (es)
PE (1) PE20190261A1 (es)
PH (1) PH12018502054A1 (es)
SA (1) SA518400355B1 (es)
SG (1) SG11201808434WA (es)
UA (1) UA124148C2 (es)
WO (1) WO2017191560A1 (es)
ZA (1) ZA201808044B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX375354B (es) 2013-03-13 2025-03-06 Prothena Biosciences Ltd Anticuerpos que se unen a tau y usos de los mismos.
UA126272C2 (uk) 2015-06-05 2022-09-14 Дженентек, Інк. Антитіло проти тау-білка та спосіб його застосування
EA201892412A1 (ru) 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед Антитела, распознающие тау
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
CA3022673A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
AR110321A1 (es) 2016-12-07 2019-03-20 Genentech Inc Anticuerpos antitau y métodos de uso
KR20240035636A (ko) 2016-12-07 2024-03-15 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
SG11201907422RA (en) 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
NZ762251A (en) 2017-10-16 2025-12-19 Eisai R&D Man Co Ltd Anti-tau antibodies and uses thereof
EA202091012A1 (ru) 2017-10-25 2020-08-27 Янссен Фармасьютикалз, Инк. Композиции фосфорилированных тау-пептидов и их применения
CA3118818A1 (en) * 2018-11-08 2020-05-14 Prothena Biosciences Limited Antibodies recognizing tau
EP3877410A4 (en) * 2018-11-08 2022-08-10 Prothena Biosciences Limited ANTIBODIES RECOGNIZING TAU PROTEIN
CN113710269A (zh) 2019-02-08 2021-11-26 Ac免疫有限公司 磷酸化Tau肽疫苗的安全施用方法
CN119371527A (zh) 2019-03-03 2025-01-28 普罗塞纳生物科学有限公司 识别tau的抗体
WO2020227515A1 (en) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
JP2023526500A (ja) 2020-05-19 2023-06-21 オター プロシーナ リミテッド アルツハイマー病の処置のためのマルチエピトープワクチン
EP4192497A4 (en) 2020-08-07 2024-08-21 Othair Prothena Limited MULTI-EPITOPIC VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
AU2022219986A1 (en) * 2021-02-14 2023-08-31 Prothena Biosciences Limited Methods of using antibodies recognizing tau
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN120019071A (zh) 2022-09-15 2025-05-16 沃雅戈治疗公司 Tau结合化合物
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU6014094A (en) 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
DK0673418T3 (da) 1992-12-14 1999-03-01 Innogenetics Nv Monoklonale antistoffer rettet mod mikrotubulusassocieret tau-protein, hybridomaer, der secernerer disse antistoffer, antig
JP3926839B2 (ja) 1993-09-14 2007-06-06 エピミューン，インコーポレイティド 万能ｄｒ−結合性ペプチドを用いる免疫応答の改変
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
FR2755144B1 (fr) * 1996-10-29 1998-11-27 Rhone Poulenc Rorer Sa Fragments d'anticorps a chaine unique anti-p53 et utilisation
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
DE60045319D1 (de) 1999-02-05 2011-01-13 Samsung Electronics Co Ltd Verfahren und Vorrichtung zum Wiederauffinden von Texturbildern
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
WO2003057838A2 (en) 2001-12-28 2003-07-17 Abgenix, Inc. Antibodies against the muc18 antigen
ES2352668T3 (es) 2002-08-14 2011-02-22 Mitsubishi Chemical Medience Corporation Anticuerpo específico para una proteína tau del sistema nervioso central.
ES2293096T3 (es) 2002-11-29 2008-03-16 BOEHRINGER INGELHEIM PHARMA GMBH &amp; CO. KG Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada.
US7847146B2 (en) 2003-03-28 2010-12-07 Baylor College Of Medicine Model for neurodegenerative disorders
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
US20050132424A1 (en) 2003-10-21 2005-06-16 Envivo Pharmaceuticals, Inc. Transgenic flies expressing Abeta42-Dutch
JP2008520186A (ja) 2004-10-01 2008-06-19 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 哺乳類ｅａｇ１イオンチャネルタンパク質に対する新規の抗体
PL1820022T3 (pl) 2004-11-10 2009-11-30 Boehringer Ingelheim Pharma Zastosowanie analizy metodą cytometrii przepływowej w optymalizacji strategii dla banków komórek jajnika chińskiego chomika
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
WO2006074071A1 (en) 2004-12-30 2006-07-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Framework residue substituted humanized col-1 antibodies and their use
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
CA2655634A1 (en) 2006-06-16 2007-12-27 Envivo Pharmaceuticals, Inc. Transgenic flies expressing tau and amyloid precursor fragment
WO2007147213A1 (en) 2006-06-22 2007-12-27 Walter And Eliza Hall Institute Of Medical Research Structure of the insulin receptor ectodomain
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
US20100216703A1 (en) 2006-08-14 2010-08-26 The Regents Of The University Of California Inhibitors of PDE4 and Methods of Use
EP2097097B1 (en) 2006-12-01 2018-05-30 E. R. Squibb & Sons, L.L.C. Antibodies, in particular human antibodies, that bind cd22 and uses thereof
DK2099823T4 (da) 2006-12-01 2022-05-09 Seagen Inc Målbindingsmiddelvarianter og anvendelser deraf
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
PT2099826E (pt) 2007-01-05 2014-01-09 Univ Zuerich Anticorpo anti-beta-amilóide e suas utilizações
PL2118300T3 (pl) 2007-02-23 2015-11-30 Prothena Biosciences Ltd Zapobieganie i leczenie synukleinopatii i amyloidozy
JP5467415B2 (ja) 2007-03-02 2014-04-09 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト タンパク質製造の改良
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
JP2009056790A (ja) 2007-09-03 2009-03-19 Takao Otogawa ファイル用ポケット
AU2008303796B2 (en) 2007-09-26 2014-09-18 Amgen Inc. Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
US9272030B2 (en) * 2007-10-17 2016-03-01 Janssen Sciences Ireland Uc Use of tau to monitor immunotherapy
MX2010005282A (es) 2007-11-13 2010-08-31 Teva Pharma Anticuerpos humanizados contra tl1a.
JP2010014691A (ja) 2008-06-20 2010-01-21 Igaku Seibutsugaku Kenkyusho:Kk 腹水中のメソテリン及び／又は巨核球増強因子を検出するための方法、キット、試薬及び装置
KR101772706B1 (ko) 2008-08-18 2017-08-29 화이자 인크. Ｃｃｒ２에 대한 항체
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
EP3683317A3 (en) 2009-05-13 2020-09-30 Genzyme Corporation Anti-human cd52 immunoglobulins
CA3239368A1 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
US20110045534A1 (en) 2009-08-20 2011-02-24 Cell Signaling Technology, Inc. Nucleic Acid Cassette For Producing Recombinant Antibodies
AU2010286501B2 (en) 2009-08-28 2015-06-11 The Board Of Regents Of The University Of Texas System Antibodies that bind Tau oligomers
WO2011053565A2 (en) 2009-10-29 2011-05-05 Biomedical Sciences Research Centre "Alexander Fleming" Compositions and methods for detecting a tauopathy
WO2011075636A2 (en) 2009-12-18 2011-06-23 Amgen Inc. Wise binding agents and epitopes
JP5697044B2 (ja) * 2010-01-08 2015-04-08 国立大学法人京都大学 タウオパチー治療用ワクチン
NZ601293A (en) 2010-02-23 2014-10-31 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
ITRM20100320A1 (it) 2010-06-11 2011-12-11 Consiglio Nazionale Ricerche Metodo per la diagnostica e il trattamento delle taupatie
US20120023911A1 (en) 2010-07-28 2012-02-02 Gm Global Technology Operations, Inc. Detection of exhaust particulate filter substrate failure
SG189174A1 (en) 2010-10-11 2013-05-31 Biogen Idec Internat Neuroscience Gmbh Human anti-tau antibodies
US9891232B2 (en) * 2010-11-09 2018-02-13 Sarcotein Diagnostics, Llc BIN1 expression as a marker of skeletal muscle mass and neurological conditions
EP2673635A4 (en) 2011-02-07 2015-08-12 Neotope Biosciences Ltd IMMUNOTHERAPY THROUGH APOE
WO2012149365A2 (en) 2011-04-27 2012-11-01 Northwestern University Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies
GB201109238D0 (en) 2011-06-01 2011-07-13 Antitope Ltd Antibodies
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
BR112014004162A2 (pt) 2011-08-22 2018-04-24 Cangene Corp anticorpos contra clostridium difficile
US9518101B2 (en) * 2011-09-19 2016-12-13 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
TWI573590B (zh) 2011-09-20 2017-03-11 雷希爾生藥有限公司 治療自體免疫疾病之組成物及方法
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
ES2600915T3 (es) * 2011-10-07 2017-02-13 Ac Immune S.A. Anticuerpos fosfoespecíficos que reconocen Tau
AR090352A1 (es) 2012-03-28 2014-11-05 Sanofi Sa Anticuerpos frente a los ligandos del receptor b1 de bradicinina
EP2834270B1 (en) 2012-04-05 2019-10-30 AC Immune S.A. Humanized tau antibody
US9428864B2 (en) 2012-04-18 2016-08-30 E I Du Pont De Nemours And Company Multilayered sheet
JP6345655B2 (ja) 2012-07-03 2018-06-20 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ タウに対する抗体
DK2885010T3 (da) 2012-08-16 2020-02-03 Ipierian Inc Fremgangsmåder til behandling med tauopati
US20140056901A1 (en) * 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
EP4356927A3 (en) * 2012-10-12 2024-10-02 Arizona Board of Regents on behalf of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
HRP20201422T1 (hr) * 2012-12-21 2021-02-19 Biogen Ma Inc. Ljudska anti-tau antitijela
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
US9364191B2 (en) 2013-02-11 2016-06-14 University Of Rochester Method and apparatus of spectral differential phase-contrast cone-beam CT and hybrid cone-beam CT
MX375354B (es) 2013-03-13 2025-03-06 Prothena Biosciences Ltd Anticuerpos que se unen a tau y usos de los mismos.
EP3418430B1 (en) * 2013-03-15 2023-03-29 The Trustees of the University of Pennsylvania Blood biomarkers that predict persistent cognitive dysfunction after concussion
CA2903091C (en) 2013-03-15 2022-09-06 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
AU2014308751B2 (en) 2013-08-22 2020-03-05 Acceleron Pharma, Inc. TGF-beta receptor type II variants and uses thereof
CN111569063A (zh) 2013-11-27 2020-08-25 伊皮埃里安股份有限公司 治疗tau病变的方法
CN106030310B (zh) 2013-12-13 2019-01-04 通用医疗公司 可溶性高分子量(hmw)tau种类及其应用
MX379030B (es) 2013-12-17 2025-03-10 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
US9629801B2 (en) * 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
US20150253341A1 (en) 2014-02-10 2015-09-10 Merck Sharp & Dohme Corp. Quantification of tau in biological samples by immunoaffinity enrichment and mass spectrometry
NZ727020A (en) 2014-06-26 2022-02-25 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
HRP20210124T1 (hr) * 2014-11-19 2021-03-19 Axon Neuroscience Se Humanizirana tau antitijela u alzheimerovoj bolesti
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
EP3261670A4 (en) 2015-02-24 2018-08-01 Rpeptide, LLC Anti-tau antibodies
UA126272C2 (uk) 2015-06-05 2022-09-14 Дженентек, Інк. Антитіло проти тау-білка та спосіб його застосування
WO2016201434A2 (en) 2015-06-12 2016-12-15 C2N Diagnostics, Llc Stable formulations of humanized anti-tau antibody
MX2017015908A (es) 2015-07-06 2018-03-15 Ucb Biopharma Sprl Anticuerpos de union a tau.
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
CN107849125A (zh) 2015-07-21 2018-03-27 生命北极神经科学公司 用于治疗靶向聚集的肽的创伤性脑损伤的方法
EP3359569A2 (en) 2015-10-06 2018-08-15 Alector LLC Anti-trem2 antibodies and methods of use thereof
CA3022673A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
EA201892412A1 (ru) 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед Антитела, распознающие тау
CA3022515A1 (en) * 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
US10947302B2 (en) 2016-11-04 2021-03-16 The Regents Of The University Of California Compositions targeting 3-repeat tau for the treatment of neurodegenerative disorders, and methods for making and using them
AR110321A1 (es) 2016-12-07 2019-03-20 Genentech Inc Anticuerpos antitau y métodos de uso
KR20240035636A (ko) 2016-12-07 2024-03-15 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
SG11201907422RA (en) 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
WO2018156250A1 (en) 2017-02-21 2018-08-30 Remd Biotherapeutics, Inc. Cancer treatment using antibodies that bind cytotoxic t-lymphocyte antigen-4 (ctla-4)
TWI771389B (zh) 2017-03-16 2022-07-21 美商健生生物科技公司 抗phf-tau抗體及其用途
MX2019011423A (es) 2017-03-28 2019-11-01 Genentech Inc Metodos de tratamiento de enfermedades neurodegenerativas.
KR20190133191A (ko) 2017-03-28 2019-12-02 얀센 백신스 앤드 프리벤션 비.브이. 타우에 특이적으로 결합하는 결합 분자
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
CN110770253A (zh) 2017-06-16 2020-02-07 百时美施贵宝公司 用于治疗tau蛋白病的组合物和方法
NZ762251A (en) 2017-10-16 2025-12-19 Eisai R&D Man Co Ltd Anti-tau antibodies and uses thereof
US11591385B2 (en) 2017-11-09 2023-02-28 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
WO2019110571A1 (en) 2017-12-04 2019-06-13 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
TW202003036A (zh) 2018-03-23 2020-01-16 德商艾伯維德國有限及兩合公司 穩定水性抗-tau抗體調配物
WO2019186276A2 (en) 2018-03-28 2019-10-03 Axon Neuroscience Se Antibody-based methods of detecting and treating alzheimer's disease
WO2019207159A1 (en) 2018-04-27 2019-10-31 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
CA3118818A1 (en) 2018-11-08 2020-05-14 Prothena Biosciences Limited Antibodies recognizing tau
EP3877410A4 (en) 2018-11-08 2022-08-10 Prothena Biosciences Limited ANTIBODIES RECOGNIZING TAU PROTEIN
CN113490505A (zh) 2018-11-19 2021-10-08 德克萨斯大学系统董事会 用于治疗tau蛋白病的tau肽抗原及与其结合的抗体
CN113597431B (zh) 2019-02-08 2025-02-21 普罗塞纳生物科学有限公司 识别Tau的抗体
CN119371527A (zh) 2019-03-03 2025-01-28 普罗塞纳生物科学有限公司 识别tau的抗体
EP3947446A1 (en) 2019-03-25 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species
GB2600599B (en) 2019-07-15 2025-05-21 Adel Inc Anti-Tau antibody and use thereof

Also Published As

Publication number Publication date
US10889638B2 (en) 2021-01-12
US11584791B2 (en) 2023-02-21
IL262726A (en) 2018-12-31
JP7481726B2 (ja) 2024-05-13
IL262726B1 (en) 2024-03-01
CN109219615B (zh) 2022-12-09
AU2017259038A1 (en) 2018-10-11
JP2019525724A (ja) 2019-09-12
CO2018012986A2 (es) 2018-12-14
CL2018003112A1 (es) 2019-02-15
SA518400355B1 (ar) 2023-11-15
UA124148C2 (uk) 2021-07-28
EA201892417A1 (ru) 2019-05-31
JP2022169598A (ja) 2022-11-09
EP3452508A1 (en) 2019-03-13
AU2017259038B2 (en) 2024-05-23
NZ746574A (en) 2025-08-29
SG11201808434WA (en) 2018-10-30
PH12018502054A1 (en) 2019-06-24
IL262726B2 (en) 2024-07-01
US20190330314A1 (en) 2019-10-31
ZA201808044B (en) 2020-02-26
BR112018072389A2 (pt) 2019-02-19
KR102471787B1 (ko) 2022-11-29
CU24537B1 (es) 2021-07-02
CN109219615A (zh) 2019-01-15
US20230250161A1 (en) 2023-08-10
MX2018013384A (es) 2019-02-28
CA3022515A1 (en) 2017-11-09
PE20190261A1 (es) 2019-02-25
WO2017191560A1 (en) 2017-11-09
MY198194A (en) 2023-08-09
KR20190003647A (ko) 2019-01-09
US20210130449A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
CU24537B1 (es) Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 3d6
CU20180135A7 (es) Anticuerpos monoclonales aislados que compiten por la unión a tau con el anticuerpo 3d6
CL2021000517A1 (es) Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003)
MX2021015880A (es) Fragmentos de unión al antígeno cd3 y composiciones que comprenden los mismos.
CU24446B1 (es) Un anticuerpo monoclonal humanizado que se une a tau
CL2017001866A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
EA201891694A1 (ru) Фармацевтическая композиция, содержащая конструкты биспецифических антител
PE20151289A1 (es) Anticuerpos que se unen al tl1a y sus usos
MX2018003410A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
CU20190087A7 (es) Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1
CL2012000254A1 (es) Anticuerpo aislado de unión a antígeno que se une a proteína atenuante de linfocitos b y t (btla); ácido nucleico que lo codifica; composición que comprende a dicho anticuerpo; y vector de expresión.
JP2014518898A5 (es)
CL2014001074A1 (es) Anticuerpos monoclonales que es anti proteina de union a adn de tar de 43 kda (tdp-43); polinucleotido que lo codifica; composicion farmaceutica que lo contiene; uso del anticuerpo.
MX366359B (es) Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1).
PH12016501937A1 (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
PE20201149A1 (es) Anticuerpos de union a hla-a2/wt1
CO2017004753A2 (es) Anticuerpos que se unen a ccr6
EA201890423A1 (ru) Слитые белки фактора ix, способы их получения и применения
NZ629682A (en) Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
CU20200105A7 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika
CO2021014153A2 (es) Anticuerpo monoclonal que se une específicamente a gitr
PH12015501632A1 (en) Humanized anti-hmgbi antibody or antigen-binding fragment thereof
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
CL2020002459A1 (es) Variantes de anticuerpo c-terminales
BR112015021964A2 (pt) Anticorpo isolado ou um fragmento ligante de antígenos do mesmo que se liga especificamente a cxcl13, composição e seus usos